London Esketamine Clinic is proud to announce delivering the first Esketamine nasal spray session in the private sector in the UK. This session was delivered at our centre at 100 Harley Centre in London on Monday 14th September 2020.

Esketamine nasal spray has recently been licenced by the Medical and Healthcare Products Regulatory Agency (MHRA) in the UK as a treatment for moderate to severe treatment-resistant depression that is also referred to as difficult to treat depression.

Esketamine nasal spray is the first licenced antidepressant in 30 years with a different mechanism of action from other available antidepressants as it works on the glutamate system of the brain. What is also remarkable is the fact that some patients start feeling an improvement of their depressive symptoms as early as 24 hours from the first dose.

esketamine nasal spray for treatment of depression

Awareness of the negative impact depression has on individuals and societies has been growing over the last two decades. It is estimated that more than 40 million people suffer with depression in Europe and that up to 50% of chronic sick leave in Europe is secondary to depression and anxiety.

Unfortunately, about 30% of individuals suffering from depression fail to respond adequately to traditional antidepressants and for a number of decades ECT was seen as the golden standard for this group of patients. However, ECT has potential serious side effects. This is why some patients suffering with treatment-resistant depression do not want to have ECT despite not responding to traditional antidepressants. Over the last 15 years new treatment modalities started becoming available for this group of patients, these new treatments include Transcranial Magnetic Stimulation (TMS) and Esketamine nasal spray.

TMS that has been widely used in USA after FDA approved the first TMS device for the treatment of depression in 2008. In the UK we were quite delayed compared to the USA in adopting this safe and effective new treatment modality. National Institute for health and Care Excellence (NICE) recommended TMS as a treatment for depression in 2015.

We offer our patients with a hight standard bespoke TMS service through London TMS Centre. We understand that depression is a complex illness and thus patients deserve to have multiple treatment options available for them to choose from. This drives our passion to provide our patients with evidence-based treatments that help them recover from depression.

We have been working relentlessly over the last few months to start offering Esketamine nasal spray to our patients through our newly established service, London Esketamine Clinic. Both London TMS Centre and London Esketamine Clinic are services of Dyad Medical private health provider. Both services operate from 100 Harley Street in central London.

If you or one of your loved ones suffer from treatment-resistant depression or difficult to treat depression and you would like to explore TMS or Esketamine nasal spray as a possible treatment option please check our website or contact us for more information.